CSF proteome: a protein repository for potential biomarker identification

Proteomic analysis is not limited to the analysis of serum or tissues. Synovial, peritoneal, pericardial and cerebrospinal fluid represent unique proteomes for disease diagnosis and prognosis. In particular, cerebrospinal fluid serves as a rich source of putative biomarkers that are not solely limited to neurologic disorders. Peptides, proteolytic fragments and antibodies are capable of crossing the blood–brain barrier, thus providing a repository of pathologic information. Proteomic technologies such as immunoblotting, isoelectric focusing, 2D gel electrophoresis and mass spectrometry have proven useful for deciphering this unique proteome. Cerebrospinal fluid proteins are generally less abundant than their corresponding serum counterparts, necessitating the development and use of sensitive analytical techniques. This review highlights some of the promising areas of cerebrospinal fluid proteomic research and their clinical applications.

[1]  Juan Manuel Maler,et al.  Tau protein phosphorylated at threonine 181 in CSF as a neurochemical biomarker in Alzheimer’s disease , 2007, Journal of Molecular Neuroscience.

[2]  Anders Wallin,et al.  Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. , 2005, Clinical chemistry.

[3]  M. Wiesmann,et al.  S-100 protein plasma levels after aneurysmal subarachnoid haemorrhage , 2005, Acta Neurochirurgica.

[4]  C. Ball,et al.  Submission of Microarray Data to Public Repositories , 2004, PLoS biology.

[5]  P. Lescuyer,et al.  Identification of post‐mortem cerebrospinal fluid proteins as potential biomarkers of ischemia and neurodegeneration , 2004, Proteomics.

[6]  Paul T. Spellman,et al.  Standards for microarray data: an open letter. , 2004, Environmental health perspectives.

[7]  Jean-Charles Sanchez,et al.  Cystatin C as a potential cerebrospinal fluid marker for the diagnosis of Creutzfeldt‐Jakob disease , 2004, Proteomics.

[8]  C. Ball,et al.  Microarray Data Standards: An Open Letter , 2004, Environmental Health Perspectives.

[9]  Jean-Paul Noben,et al.  Proteomic analysis of cerebrospinal fluid from multiple sclerosis patients , 2004, Proteomics.

[10]  R. Neumar,et al.  Proteins released from degenerating neurons are surrogate markers for acute brain damage , 2004, Neurobiology of Disease.

[11]  A. Saiz,et al.  Tau protein in cerebrospinal fluid: a possible marker of poor outcome in patients with early relapsing-remitting multiple sclerosis , 2004, Neuroscience Letters.

[12]  M. Willis,et al.  Nasal Discharge in a 50-Year-Old Woman , 2004 .

[13]  David C Christiani,et al.  Urinary 8-hydroxy-2'-deoxyguanosine as a biomarker of oxidative DNA damage in workers exposed to fine particulates. , 2004, Environmental health perspectives.

[14]  T. Beems,et al.  Glial and neuronal proteins in serum predict outcome after severe traumatic brain injury , 2004, Neurology.

[15]  C. Kahn,et al.  Role for neuronal insulin resistance in neurodegenerative diseases. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[16]  A. Godbolt,et al.  The prevalence of oligoclonal bands in the CSF of patients with primary neurodegenerative dementia , 2004, Journal of Neurology.

[17]  Jean-Charles Sanchez,et al.  Fatty Acid Binding Protein as a Serum Marker for the Early Diagnosis of Stroke , 2004, Molecular & Cellular Proteomics.

[18]  W. White,et al.  Novel Diagnostic Test for Acute Stroke , 2003, Stroke.

[19]  M. Lovell,et al.  Proteomic analysis of human ventricular cerebrospinal fluid from neurologically normal, elderly subjects using two-dimensional LC-MS/MS. , 2004, Journal of proteome research.

[20]  Stephen A. Williams,et al.  Proteomic approaches in drug discovery and development. , 2004, International review of neurobiology.

[21]  J. Masjuán,et al.  An ultrasensitive method for the detection of oligoclonal IgG bands. , 2004, Journal of immunological methods.

[22]  Katharina Buerger,et al.  Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study. , 2004, Archives of general psychiatry.

[23]  G. Giovannoni,et al.  The clinical significance of an intrathecal monoclonal immunoglobulin band: a follow-up study. , 2004, Neurology.

[24]  Emanuel F. Petricoin,et al.  Biomarker Amplification by Serum Carrier Protein Binding , 2004, Disease markers.

[25]  K. Wang,et al.  Elevation of CRABP-I in the Cerebrospinal Fluid of Patients With Moyamoya Disease , 2003, Stroke.

[26]  N. Morakkabati-Spitz,et al.  Paraneoplastic neurological syndrome: patient with anti-Yo antibody and breast cancer: a case report , 2003, Archives of Gynecology and Obstetrics.

[27]  M. Ferrari,et al.  Clinical proteomics: Written in blood , 2003, Nature.

[28]  Kaj Blennow,et al.  Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer's disease. , 2003, Brain research. Molecular brain research.

[29]  D. Laskowitz,et al.  Early biomarkers of stroke. , 2003, Clinical chemistry.

[30]  D. Berg,et al.  14-3-3 proteins in the nervous system , 2003, Nature Reviews Neuroscience.

[31]  J. Martín,et al.  A prospective study of CSF markers in 250 patients with possible Creutzfeldt–Jakob disease , 2003, Journal of neurology, neurosurgery, and psychiatry.

[32]  A. Kazis,et al.  What Can be Worse Than Cerebral Tuberculosis?: A Concommitant Aspergillus Infection , 2003 .

[33]  F. Graus,et al.  Qualitative evidence of anti-Yo-specific intrathecal antibody synthesis in patients with paraneoplastic cerebellar degeneration , 2003, Journal of Neuroimmunology.

[34]  Rob Pieters,et al.  Identification of Tumor‐Related Proteins by Proteomic Analysis of Cerebrospinal Fluid from Patients with Primary Brain Tumors , 2003, Journal of neuropathology and experimental neurology.

[35]  D. Hochstrasser,et al.  A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer's disease , 2003, Proteomics.

[36]  J. Tavernier,et al.  The ins and outs of leptin receptor activation , 2003, FEBS letters.

[37]  P. Davidsson,et al.  Elevated Levels of alpha-2-Heremans-Schmid Glycoprotein in CSF of Patients with Low-Grade Gliomas , 2003, Tumor Biology.

[38]  P. Lewczuk,et al.  The amyloid-β (Aβ) peptide pattern in cerebrospinal fluid in Alzheimer's disease: evidence of a novel carboxyterminally elongated Aβ peptide , 2003 .

[39]  D. Desiderio,et al.  Proteomics analysis of phosphotyrosyl-proteins in human lumbar cerebrospinal fluid. , 2003, Journal of proteome research.

[40]  M. Iadarola,et al.  Cystatin C as a cerebrospinal fluid biomarker for pain in humans , 2003, Pain.

[41]  Emanuel F Petricoin,et al.  Protein microarrays: meeting analytical challenges for clinical applications. , 2003, Cancer cell.

[42]  M. Trojano,et al.  Quality Assurance for Cerebrospinal Fluid Protein Analysis: International Consensus by an Internet-Based Group Discussion , 2003, Clinical chemistry and laboratory medicine.

[43]  H. Möller,et al.  Differentiation of geriatric major depression from Alzheimer's disease with CSF tau protein phosphorylated at threonine 231. , 2003, The American journal of psychiatry.

[44]  Gavin Sherlock,et al.  Microarray databases: storage and retrieval of microarray data. , 2003, Methods in molecular biology.

[45]  P. Lewczuk,et al.  The amyloid-beta (Abeta) peptide pattern in cerebrospinal fluid in Alzheimer's disease: evidence of a novel carboxyterminally elongated Abeta peptide. , 2003, Rapid communications in mass spectrometry : RCM.

[46]  David Botstein,et al.  The Stanford Microarray Database: data access and quality assessment tools , 2003, Nucleic Acids Res..

[47]  K. Blennow,et al.  Studies of the pathophysiological mechanisms in frontotemporal dementia by proteome analysis of CSF proteins. , 2002, Brain research. Molecular brain research.

[48]  W. Mutschler,et al.  Serum S-100B and interleukin-8 as predictive markers for comparative neurologic outcome analysis of patients after cardiac arrest and severe traumatic brain injury* , 2002, Critical care medicine.

[49]  K. Blennow,et al.  Identification of proteins in human cerebrospinal fluid using liquid-phase isoelectric focusing as a prefractionation step followed by two-dimensional gel electrophoresis and matrix-assisted laser desorption/ionisation mass spectrometry. , 2002, Rapid communications in mass spectrometry : RCM.

[50]  W. Mutschler,et al.  Immediate S-100B and Neuron-Specific Enolase Plasma Measurements for Rapid Evaluation of Primary Brain Damage in Alcohol-Intoxicated, Minor Head-Injured Patients , 2002, Shock.

[51]  Duccio Cavalieri,et al.  Standards for Microarray Data , 2002, Science.

[52]  E. Jauch,et al.  C-tau biomarker of neuronal damage in severe brain injured patients: association with elevated intracranial pressure and clinical outcome , 2002, Brain Research.

[53]  Jason E. Stewart,et al.  Design and implementation of microarray gene expression markup language (MAGE-ML) , 2002, Genome Biology.

[54]  A. Sickmann,et al.  Towards a high resolution separation of human cerebrospinal fluid. , 2002, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[55]  J. Kornhuber,et al.  Highly conserved and disease‐specific patterns of carboxyterminally truncated Aβ peptides 1–37/38/39 in addition to 1–40/42 in Alzheimer's disease and in patients with chronic neuroinflammation , 2002, Journal of neurochemistry.

[56]  T. Nagatsu,et al.  Parkinson's disease: changes in apoptosis-related factors suggesting possible gene therapy , 2002, Journal of Neural Transmission.

[57]  W. Mutschler,et al.  Rapid identification of high-risk patients after minor head trauma (MHT) by assessment of S-100B: ascertainment of a cut-off level. , 2002, European journal of medical research.

[58]  Kaj Blennow,et al.  Proteome analysis of cerebrospinal fluid proteins in Alzheimer patients , 2002, Neuroreport.

[59]  D. Desiderio,et al.  Analysis of the human lumbar cerebrospinal fluid proteome , 2002, Electrophoresis.

[60]  W. Mutschler,et al.  Assessment of Early Brain Damage in Carotid Endarterectomy: Evaluation of S-100B Serum Levels and Somatosensory Evoked Potentials in a Pilot Study , 2002, World Journal of Surgery.

[61]  C. Woertgen,et al.  High serum S100B levels for trauma patients without head injuries. , 2001, Neurosurgery.

[62]  Jason E. Stewart,et al.  Minimum information about a microarray experiment (MIAME)—toward standards for microarray data , 2001, Nature Genetics.

[63]  G. Sedvall,et al.  Characterization of Human Cleaved N-CAM and Association with Schizophrenia , 2001, Experimental Neurology.

[64]  W. Mutschler,et al.  Elevated serum levels of S-100B reflect the extent of brain injury in alcohol intoxicated patients after mild head trauma. , 2001, Shock.

[65]  R. Anderson,et al.  High Serum S100B Levels for Trauma Patients without Head Injuries , 2001, Neurosurgery.

[66]  K. Blennow,et al.  The Cerebrospinal Fluid Levels of Tau, Growth-Associated Protein-43 and Soluble Amyloid Precursor Protein Correlate in Alzheimer’s Disease, Reflecting a Common Pathophysiological Process , 2001, Dementia and Geriatric Cognitive Disorders.

[67]  W. Mutschler,et al.  Early cellular brain damage and systemic inflammatory response after cardiopulmonary resuscitation or isolated severe head trauma: a comparative pilot study on common pathomechanisms. , 2001, Resuscitation.

[68]  D. Hochstrasser,et al.  Assessing cerebrospinal fluid rhinorrhea: A two‐dimensional electrophoresis approach , 2001, Electrophoresis.

[69]  K. Blennow,et al.  Identification of the apolipoprotein E4 isoform in cerebrospinal fluid with preparative two‐dimensional electrophoresis and matrix assisted laser desorption/ionization‐time of flight‐mass spectrometry , 2001, Electrophoresis.

[70]  T. Mussack,et al.  S-100b, sE-selectin, and sP-selectin for Evaluation of Hypoxic Brain Damage in Patients after Cardiopulmonary Resuscitation: Pilot Study , 2001, World Journal of Surgery.

[71]  J. Johansson,et al.  Peptide repertoire of human cerebrospinal fluid: novel proteolytic fragments of neuroendocrine proteins. , 2001, Journal of chromatography. B, Biomedical sciences and applications.

[72]  K. Blennow,et al.  Proteome studies of human cerebrospinal fluid and brain tissue using a preparative two‐dimensional electophoresis approach prior to mass spectrometry , 2001, Proteomics.

[73]  S. Yamaguchi,et al.  Nicotinamide-N-methyltransferase is higher in the lumbar cerebrospinal fluid of patients with Parkinson's disease , 2001, Neuroscience Letters.

[74]  K. Blennow,et al.  Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke , 2001, Neuroscience Letters.

[75]  David Botstein,et al.  The Stanford Microarray Database , 2001, Nucleic Acids Res..

[76]  R. Midgard,et al.  Oligoclonal bands in cerebrospinal fluid:a comparative study of isoelectric focusing, agarose gel electrophoresis and IgG index , 2000, Acta neurologica Scandinavica.

[77]  A. Sickmann,et al.  Identification of proteins from human cerebrospinal fluid, separated by two‐dimensional polyacrylamide gel electrophoresis , 2000, Electrophoresis.

[78]  P. Verhaert,et al.  Identification of two‐dimensionally separated human cerebrospinal fluid proteins by N‐terminal sequencing, matrix‐assisted laser desorption/ionization — mass spectrometry, nanoliquid chromatography‐electrospray ionization‐time of flight‐mass spectrometry, and tandem mass spectrometry , 2000, Electrophoresis.

[79]  C. Parvin,et al.  Leptin in cerebrospinal fluid from children: correlation with plasma leptin, sexual dimorphism, and lack of protein binding. , 2000, Clinical chemistry.

[80]  C. Rohlff.  Proteomics in molecular medicine: Applications in central nervous systems disorders , 2000, Electrophoresis.

[81]  H. Ichinose,et al.  Cytokines in Parkinson's disease. , 2000, Journal of neural transmission. Supplementum.

[82]  T. Mussack,et al.  S-100b as a screening marker of the severity of minor head trauma (MHT)--a pilot study. , 2000, Acta neurochirurgica. Supplement.

[83]  K. Blennow,et al.  CSF levels of tau, β-amyloid1–42 and GAP-43 in frontotemporal dementia, other types of dementia and normal aging , 2000, Journal of Neural Transmission.

[84]  H. Ichinose,et al.  Increase in level of tumor necrosis factor (TNF)-α in 6-hydroxydopamine-lesioned striatum in rats without influence of systemic l-DOPA on the TNF-α induction , 1999, Neuroscience Letters.

[85]  R. Faull,et al.  A comparative proteome analysis of hippocampal tissue from schizophrenic and Alzheimer's disease individuals , 1999, Molecular Psychiatry.

[86]  R. Rudick,et al.  Quantification of Axonal Damage in Traumatic Brain Injury , 1999, Journal of neurochemistry.

[87]  K. Tanaka,et al.  Increase in level of tumor necrosis factor (TNF)-alpha in 6-hydroxydopamine-lesioned striatum in rats without influence of systemic L-DOPA on the TNF-alpha induction. , 1999, Neuroscience letters.

[88]  M. Wunderlich,et al.  Protein S-100B and neuron specific enolase as early neurobiochemical markers of the severity of traumatic brain injury. , 1999, Restorative neurology and neuroscience.

[89]  A. Raabe,et al.  Serum S-100 and neuron-specific enolase for prediction of regaining consciousness after global cerebral ischemia. , 1998, Stroke.

[90]  K. Blennow,et al.  Processing of neuropeptide Y and somatostatin in human cerebrospinal fluid as monitored by radioimmunoassay and mass spectrometry , 1998, Peptides.

[91]  M. Wiesmann,et al.  Plasma S-100b protein concentration in healthy adults is age- and sex-independent. , 1998, Clinical chemistry.

[92]  G. Gudmundsson,et al.  Hereditary cystatin C amyloid angiopathy: monitoring the presence of the Leu-68-->Gln cystatin C variant in cerebrospinal fluids and monocyte cultures by MS. , 1998, The Biochemical journal.

[93]  J. van Loon,et al.  Detection of CSF leakage by isoelectric focusing on polyacrylamide gel, direct immunofixation of transferrins, and silver staining. , 1998, Clinical chemistry.

[94]  G. Holmgren,et al.  Detection of different forms of variant transthyretin (Met30) in cerebrospinal fluid , 1997, Neuroscience Letters.

[95]  M. Wiesmann,et al.  S-100 protein and neuron-specific enolase concentrations in blood as indicators of infarction volume and prognosis in acute ischemic stroke. , 1997, Stroke.

[96]  P. Riederer,et al.  The soluble form of Fas molecule is elevated in parkinsonian brain tissues , 1996, Neuroscience Letters.

[97]  C. Gibbs,et al.  The 14-3-3 brain protein in cerebrospinal fluid as a marker for transmissible spongiform encephalopathies. , 1996, The New England journal of medicine.

[98]  T. Nagatsu,et al.  Interleukin (IL)-1β, IL-2, IL-4, IL-6 and transforming growth factor-α levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson's disease , 1996, Neuroscience Letters.

[99]  T. Nagatsu,et al.  Interleukin (IL)-1 beta, IL-2, IL-4, IL-6 and transforming growth factor-alpha levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson's disease. , 1996, Neuroscience letters.

[100]  K. Blennow,et al.  Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? , 1995, Molecular and chemical neuropathology.

[101]  M. Wiesmann,et al.  Measurement of S-100 Protein in Human Blood and Cerebrospinal Fluid: Analytical Method and Preliminary Clinical Results , 1995, European journal of clinical chemistry and clinical biochemistry : journal of the Forum of European Clinical Chemistry Societies.

[102]  R. Deyo,et al.  The effectiveness of four interventions for the prevention of low back pain. , 1994, JAMA.

[103]  Minoru Harada,et al.  Tumor necrosis factor-α (TNF-α) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients , 1994, Neuroscience Letters.

[104]  P. Riederer,et al.  Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. , 1994, Neuroscience letters.

[105]  C. Vigo‐Pelfrey,et al.  Rapid Communication: Characterization of β‐Amyloid Peptide from Human Cerebrospinal Fluid , 1993 .

[106]  E. Bock,et al.  CSF and serum brain-specific creatine kinase isoenzyme (CK-BB), neuron-specific enolase (NSE) and neural cell adhesion molecule (NCAM) as prognostic markers for hypoxic brain injury after cardiac arrest in man , 1993, Journal of the Neurological Sciences.

[107]  K. Haglid,et al.  Determination of S‐100 and Glial Fibrillary Acidic Protein Concentrations in Cerebrospinal Fluid After Brain Infarction , 1991, Stroke.

[108]  M. Ackenheil,et al.  Analysis of cerebrospinal fluid from patients with psychiatric and neurological disorders by two‐dimensional electrophoresis: Identification of disease‐associated polypeptides as fibrin fragments , 1991, Electrophoresis.

[109]  A. Frankfurter,et al.  The distribution of tau in the mammalian central nervous system , 1985, The Journal of cell biology.

[110]  N G Anderson,et al.  High resolution two-dimensional electrophoresis of human plasma proteins. , 1977, Proceedings of the National Academy of Sciences of the United States of America.